The safety of flavocoxid, a medical food, in the dietary management of knee osteoarthritis

Journal of Medicinal Food

Volumn 12, Issue 5, 2009, Pages 1143-1148

  Morgan, Sarah L ^a,b   Baggott, Joseph E ^a   Moreland, Larry ^c   Desmond, Renee ^b,d   Kendrach, Angela C ^a,b  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d University of Alabama at Birmingham   (United States)

Author keywords

Flavocoxid; Knee; Medical food; Osteoarthritis

Indexed keywords

FLAVAN DERIVATIVE; FLAVOCOXID; FLAVONOID; PLACEBO; UNCLASSIFIED DRUG;

ABDOMINAL DISCOMFORT; ABSENCE OF SIDE EFFECTS; ACACIA; ACACIA CATECHU; ADULT; AGED; ARTICLE; BECK DEPRESSION INVENTORY; BLOOD PRESSURE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET SUPPLEMENTATION; DOUBLE BLIND PROCEDURE; DRUG SAFETY; EAR DISEASE; FEMALE; GASTROINTESTINAL TOXICITY; HAMILTON ANXIETY SCALE; HUMAN; INCIDENCE; KNEE OSTEOARTHRITIS; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; MUSCULOSKELETAL DISEASE; NEUROLOGIC DISEASE; NOSE DISEASE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SCUTELLARIA BAICALENSIS; SKIN TOXICITY; THROAT DISEASE; UROGENITAL TRACT DISEASE; URTICARIA;

ACACIA; AGED; DOUBLE-BLIND METHOD; FEMALE; FLAVONOIDS; HUMANS; KNEE JOINT; MALE; MIDDLE AGED; OSTEOARTHRITIS, KNEE; PLANT BARK; PLANT EXTRACTS; PLANT ROOTS; SCUTELLARIA BAICALENSIS;

ACACIA CATECHU; SCUTELLARIA; SCUTELLARIA BAICALENSIS;

EID: 70350515681     PISSN: 1096620X     EISSN: None     Source Type: Journal    
DOI: 10.1089/jmf.2008.0244     Document Type: Article

References (46)

1. U.S. Food and Drug Administration. http:=www.cfsan.fda.gov=-comm=cp21002. html (accessed September 19, 2008).
2. Morgan SL, Baggott JE: Medical foods: products for the management of chronic diseases. Nutr Rev 2006;64:495-501.
3. Levy R, Saikovsky R, Shmidt E, Khokhlov A: Safety and effi- cacy of flavocoxid (Limbrel) compared with naproxen in subjects with osteoarthritis of the knee: a pilot study. Osteoarthritis Cartilage 2007;15:B91-B94.
4. Burnett BP, Jia Q, Zhao Y, Levy RM: A medicinal extract of Scutellaria baicalensis and Acacia catechu acts as a dual inhibitor of cyclooxygenase and 5-lipoxygenase to reduce inflammation. J Med Food 2007;10:442-451.
5. Bodeker G, Burford G, Chamberlain J, Bhat K: The underexploited medicinal potential of Azadirachta indica A Juss (Meliaceae) and Acacia niolotic (L.) Willd, Ex Del (Leguminosae) in sub-Saharan Africa: a case for a review of priorities. Int Forest Rev 2001;4:285-298.
6. Ahmed S, Rahman A, Hasnain A, Lalonde M, Goldberg VM, Haqqi TM: Green tea polyphenol epigallocatechin-3-gallate inhibits the IL-1 beta-induced activity and expression of cyclooxygenase- 2 and nitric oxide synthase-2 in human chondrocytes. Free Radic Biol Med 2002;33:1097-1105.
7. Lin YL, Lin JK: Epigallocatechin-3-gallate blocks the induction of nitric oxide synthase by down-regulating lipopolysaccharide- induced activity of transcription factor nuclear factor B. Mol Pharmacol 1997;52:465-472.
8. Chen YC, Shen SC, Chen LG, Lee TJ, Yang LL: Wogonin, baicalin, and baicalein inhibition of inducible nitric acid synthase and cyclooxygenase-2 gene expressions induced by nitric oxide synthase inhibitors and lipopolysaccharide. Biochem Pharmacol 2001;61:1417-1427.
9. Chung HL, Yue GG, To KF, Su YL, Huang Y, Ko WH: Effect of Scutellariae Radix extract on experimental dextran-sulfate sodiuminduced colitis in rats. World J Gastroenterol 2007;13:5605-5611.
10. Enomoto R, Sugahara C, Suzuki C, et al.: Wogonin prevents glucocorticoid-induced thymocyte apopotosis without diminishing its anti-inflammatory action. J Pharmacol Sci 2007;104:355-365.
11. Hsieh CJ, Hall K, Ha T, Li C, Krishnaswamy G, Chi DS: Baicalen inhibits IL-1beta and TNF-alpha-induced inflammatory cytokine production from human mast cells via regulation of the NF-kappa B pathway. Clin Mol Allergy 2007;26:5.
12. Huang Y, Tsang SY, Yao X, Chen ZY: Biological properties of baicalein in cardiovascular system. Curr Drug Targets Cardiovasc Haematol Disord 2005;5:177-184.
13. Koga T, Meydani M: Effects of plasma metabolites of (+)- catechin and quercetin on monocyte adhesion to human aortic endothelial cells. Am J Clin Nutr 2001;73:941-948.
14. Krakauer T, Li BQ, Young HA: The flavonoid baicalin inhibits superantigen-induced inflammatory cytokines and chemokines. FEBS Lett 2001;500:52-55.
15. Lai MY, Hsiu SL, Hou YC, Tsai SY, Chao PD: Significant decrease of cyclosporine bioavailability in rats caused by a decoction of the roots of Scutellaria baicalensis. Planta Med 2004; 70:132-137.
16. Li BQ, Fui T, Gong WH, et al.: The flavonoid baicalin exhibits anti-inflammatory activity by binding to chemokines. Immunopharmacology 2000;49:295-306.
17. Makino T, Hishida A, Goda Y, Mizukami H: Comparison of the major flavonoid content of S. baicalensis, S. lateriflora, and their commercial products. J Nat Med 2008;62:294-299.
18. Mehendale S, Aung H, Wang CZ, et al.: Scutellaria baicalensis and a constituent flavonoid, baicalein, attenuate ritonavir-induced gastrointestinal side-effects. J Pharm Pharmacol 2007;59:1567-1572.
19. Park HG, Yoon SY, Choi JY, et al.: Anticonvulsant effect of wogonin isolate from Scutellaria baicalensis. Eur J Pharmacol 2007;5742:112-119.
20. Kim YO, Leem K, Park J, et al.: Cytoprotective effect of Scutellaria baicalensis in CA1 hippocampal neurons of rats after global cerebral ischemia. J Ethnopharmacol 2001;77:183-188.
21. Scheck AC, Perry K, Hank NC, Clark WD: Anticancer activity of extracts derived from the mature roots of Scutellaria baicalensis on human malignant brain tumor cells. BMC Complement Altern Med 2006;16:27.
22. Alcarez MJ, Ferrandiz ML: Modification of arachidonic acid metabolism by flavonoids. J Ethnopharmacol 1987;21:209-229.
23. Kimura Y, Kubo M, Tani T, Arichi S, Ohminami H, Okuda H: Studies on Scutellariae radix. III. Effects on lipid metabolism in serum, liver, and fat cells of rats. Chem Pharm Bull 1981;29: 2308-2312.
24. Burnett BP, Levy R, Cole BJ: Metabolic mechanisms in the pathogenesis of osteoarthritis. J Knee Surg 2006;19:191-197.
25. Final report of the safety assessment of Acacia catechu gum, Acacia concinna fruit extract, Acacia dealbata leaf extract, Acacia dealbata leaf wax, Acacia decurrens extract, Acacia farnesiana extract, Acacia farnesiana flower wax, Acacia farnesiana gum, Acacia senegal extract, Acacia senegal gum, and Acacia senegal gum extract. Int J Toxicol 2005;24:75-119.
26. Kim HM, Moon EJ, Li E, Kim KM, Nam SY, Chung CK: The nitric oxide-producing activities of Scutellaria baicalensis. Toxicology 1999;135:109-115.
27. Schmitt D, Tran N, Riefler S, et al.: Toxicologic evaluation of modified gum acacia: mutagenicity, acute and subchronic toxicity. Food Chem Toxicol 2008;46:1048-1054.
28. Burnett BP, Silva S, Mesches MH, Wilson S, Jia Q: Safety evaluation of a combination, defined extract of Scutellaria baicalensis and Acacia catechu. J Food Biochem 2007;31:797-825.
29. Altman R, Asch E, Bloch D, et al.: Development of criteria for the classification and reporting of osteoarthritis: classification of osteoarthritis of the knee. Arthritis Rheum 1986;29:1039-1049.
30. Grundy SM, Pasternak R, Greenland P, Smith S, Fuster V: Assessment of cardiovascular risk by use of multiple-risk factor assessment equations. A statement for healthcare professionals from the American Heart Association and the American College of Cardiology. Circulation 1999;100:1048-1092.
31. Hamilton M: The assessment of anxiety states by rating. Br J Med Psychol 1959;32:50-55.
32. Beck AT, Steer RA, Ball R, Ranieri WF: Comparison of Beck Depression Inventories-IA and-II in psychiatric outpatients. J Personality Assessment 1996;67:588-597.
33. Beck AT, Steer RA, Brown GK: Manual for the Beck Depression Inventory-II. Psychological Association, San Antonio, TX, 1996.
34. Steer RA, Ball R, Ranieri WF, Beck AT: Dimensions of the Beck Depression Inventory-II in clinically depressed outpatients. J Clin Psychol 1999;55:117-128.
35. Steer RA, Clark DA, Beck AT, Ranieri WF: Common and specific dimensions of self-reported anxiety and depression: the BDI-II versus the BDI-IA. Behav Res Ther 1999;37:183-190.
36. Beck AT: Beck Depression Inventory, 2nd ed. Harcourt Assessment, Inc., Oxford, UK, 1993.
37. Robak J, Gryglewiski RJ: Bioactivity of flavonoids. Pol J Pharmacol 1996;48:555-564.
38. Kang WS, Lim IH, Yuk DY, et al.: Antithrombotic activities of green tea catechins and epigallocatechin gallate. Thromb Res 1999;96:229-237.
39. Cowman MM: Plant products as antimicrobial agents. Clin Microbiol Rev 1999;12:564-583.
40. Lau AC, Yam LY, So LK: Management of critically ill patients with severe acute respiratory syndrome (SARS). Int J Med Sci 2004;1:1-10.
41. Yamada H, Takuma N, Daimon T, Hara Y: Gargling with tea catechin extracts for the prevention of influenza infection in elderly nursing home residents: a prospective clinical study. J Altern Complement Med 2006;12:669-672.
42. Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C: Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 2006;332:1302-1308.
43. Laine L, White WB, Rostom A, Hochberg M: COX-2 selective inhibitors in the treatment of osteoarthritis. Semin Arthritis Rheum 2008;38:165-187.
44. Mukherjee D: Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2002;286:954-959.
45. Mukherjee D: Selective cyclooxygenase-2 (COX-2) inhibitors and potential risk of cardiovascular events. Biochem Pharmacol 2002;63:817-821.
46. Sorensen R, Abildstrom SZ, Torp-Pedersen C, Gislason GH: Use of selective cyclo-oxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs in high doses increases mortality and risk of reinfarction in patients with prior myocardial infarction. J Cardiovasc Nurs 2008;23:14-19.